| Trial ID: | L3115 |
| Source ID: | NCT01202266
|
| Associated Drug: |
Pf-05161704 Or Placebo
|
| Title: |
A Multiple Dose Study Of PF-05161704 In Healthy Volunteers
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: PF-05161704 or Placebo|DRUG: PF-05161704 or Placebo|DRUG: PF-05161704 or Placebo|DRUG: PF-05161704 or Placebo|DRUG: PF-05161704 or Placebo|DRUG: PF-05161704 or Placebo|DRUG: PF-05161704 or Placebo|DRUG: PF-05161704 or Placebo
|
| Outcome Measures: |
Primary: Safety and tolerability endpoints evaluated by adverse event monitoring, laboratory values, cardiovascular monitoring, 2 weeks|Pharmacokinetic Endpoints: single dose and steady state pharmacokinetics of PF-05161704 and its metabolite PF-05200145. Urinary recovery will also be assessed for PF-05161704 and PF-05200145, 2 weeks | Secondary: Pharmacodynamic Endpoints: Absolute value and change from Day 0 baseline in postprandial GLP-1. Postprandial plasma PYY, triglycerides and apoB48. Absolute value and change from baseline in apoB100 and VLDL, 2 weeks|Exploratory Parameters: absolute value and change from Day 0 baseline in concentrations of fasting serum lipids and body weight, 2 weeks
|
| Sponsor/Collaborators: |
Sponsor: Pfizer
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
32
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2010-08
|
| Completion Date: |
2010-12
|
| Results First Posted: |
|
| Last Update Posted: |
2011-03-11
|
| Locations: |
Pfizer Investigational Site, New Haven, Connecticut, 06511, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01202266
|
